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Abstract Advances in molecular biology have resulted in
novel therapy for neurofibromatosis 2-related (NF2)
tumours, highlighting the need for robust outcome mea-
sures. The disease-focused NF2 impact on quality of life
(NFTI-QOL) patient questionnaire was assessed as an
outcome measure for treatment in a multi-centre study.
NFTI-QOL was related to clinician-rated severity (Clin-
Sev) and genetic severity (GenSev) over repeated visits.
Data were evaluated for 288 NF2 patients (n = 464 visits)
attending the English national NF2 clinics from 2010 to
2012. The male-to-female ratio was equal and the mean
age was 42.2 (SD 17.8) years. The analysis included NFTI-
QOL eight-item score, ClinSev graded as mild, moderate,
or severe, and GenSev as a rank order of the number of
NF2 mutations (graded as mild, moderate, severe). The
mean (SD) 8.7 (5.4) score for NFTI-QOL for either a first
visit or all visits 9.2 (5.4) was similar to the published norm
of 9.4 (5.5), with no significant relationships with age or
gender. NFTI-QOL internal reliability was good, with a
Cronbach’s alpha score of 0.85 and test re-test reliability
r = 0.84. NFTI related to ClinSev (r = 0.41, p \ 0.001;
r = 0.46 for all visits), but weakly to GenSev (r = 0.16,
p \ 0.05; r = 0.15 for all visits). ClinSev related to Gen-
Sev (r = 0.41, p \ 0.001; r = 0.42 for all visits). NFTI-
QOL showed a good reliability and ability to detect
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significant longitudinal changes in the QOL of individuals.
The moderate relationships of NFTI-QOL with clinician-
and genetic-rated severity suggest that NFTI-QOL taps into
NF2 patient experiences that are not encompassed by
ClinSev rating or genotype.
Keywords Neurofibromatosis 2  NF2  NFTI-QOL 
Vestibular schwannoma
Introduction
Neurofibromatosis 2 (NF2) is an inherited tumour sup-
pressor disease with a prevalence of 1 in 60,000 and a birth
incidence of 1 in 25–33,000 individuals [1, 2]. Bilateral
vestibular schwannomas (VS) are emblematic of NF2, but
schwannomas may form on other cranial, spinal, and
peripheral nerves. Central nervous system meningiomas
and ependymomas, peripheral neuropathy, amyotrophy,
retinal hamartomas, and subcapsular lens opacities are part
of the NF2 disease spectrum [1, 3]. Typically the pre-
senting symptoms in adults are hearing loss and balance
disturbance, and these symptoms reflect the major causes
of morbidity and impact on quality of life (QOL) in people
with NF2 [1, 3, 4]. Impaired vision and facial weakness
may compound the problems in individuals who already
have to contend with deafness. The NF2 gene was identi-
fied on chromosome 22q11.2 and somatic mosaicism is
present in about one-third of de novo patients [1, 2, 5].
Germline truncating mutations are associated with more
severe disease than large deletions and missense mutations;
individuals with germline truncating mutations are diag-
nosed at a younger age and usually have an earlier onset of
symptomatic tumours [6, 7]. Recent developments in
neurosurgery, radio-surgery, auditory rehabilitation, and
molecular biology have increased the treatment options for
individuals with NF2 [8]. Bevazicumab acts as a vascular
endothelial growth factor inhibitor that reduces vestibular
schwannoma growth and shrinks tumours in some patients;
other novel drugs are being investigated in clinical trials,
including lapatinib, a tyrosine kinase inhibitor, RAD0001
[9–11]. However, randomised controlled therapeutic trials,
the gold standard of efficacy, are difficult to undertake
because of the rarity of NF2. Assessment of genotype, in
combination with clinician- and patient-rated severity is
useful to determine therapeutic outcomes. Meticulous
clinical evaluation includes neurological and visual
examination, timed gait assessment, neurophysiology,
speech and pure tone audiometry, and serial, standardised
measurement of tumours on 1-mm magnetic resonance
imaging [1, 8]. Few studies have addressed QOL in people
with NF2. Neary et al. [12] reported that the predominant
problems were impaired balance and difficulty with social
communication when they used a closed-set questionnaire
and the generic Short Form-36 (SF-36) questionnaire to
evaluate QOL in NF2 patients [12, 13]. Patel undertook
semi-structured interviews in six patients and revealed that
NF2 had a negative impact on daily activities including
employment, and was associated with social isolation
arising from communication difficulties [4]. Family played
a central role in providing physical, psychological, and
emotional support. We developed the NF2 Impact on
Quality of Life (NFTI-QOL) questionnaire, a reliable,
validated disease-focused assessment for NF2 patients, for
health-care providers to use as a clinical assessment tool
and outcome measure (Table 1) [14]. The questionnaire is
completed in a few minutes and comprises eight questions,
with a maximum score of 24 reflecting the greatest impact
on QOL. There is a free-response section at the end if
individuals wish to add expand an answer and add new
information. NFTI-QOL covers the domains of balance and
dizziness, hearing, facial weakness, sight, mobility and
walking, role and outlook on life, pain, anxiety, and
depression [14] (Table 1).
Aims
The aim of this study was to evaluate the NFTI-QOL as an
assessment tool and potential outcome measure for thera-
peutic intervention in multi-centre national NF2 clinical
services. Patient-reported experience using the NFTI-QOL
was related to clinician-rated and genetic severity (Gen-
Sev) scores. Changes over repeated clinic visits were
evaluated to detect stable disease and changes after
intervention.
Methods
Ethical approval
The study was approved as a clinical evaluation, with study
number 3711, by the Clinical Audit Group committee at
Guy’s and St Thomas’ National Health Service (NHS)
Foundation Trust, London.
Participating centres, inclusion and exclusion criteria
NIFTI-QOL data were collected for all patient visits to the
national NF2 services at Guy’s and St. Thomas’ NHS
Foundation Trust, Oxford University Hospitals NHS Trust,
Addenbrooke’s Hospital, Cambridge University NHS
Foundation Trust, Central Manchester University Hospitals
Foundation Trust, and satellite NF2 services from April
J Neurol
123
2010 to October 2012. Individuals who did not fulfil the
diagnostic criteria for generalised or mosaic NF2, or who
were aged \16 years were excluded from the study. Age
and gender were recorded for all patients.
Clinician-rated severity
Clinician-rated severity was assessed as severe, moderate,
or mild and was determined during the clinical visit. Severe
Table 1 NFTI-QOL English version for the UK (neurofibromatosis 2 impact on quality of life) (reproduced with permission from Hornigold
et al. [14])
J Neurol
123
disease was classified as symptomatic presentation at age
\20 years with at least two symptomatic or large tumours
[1.5 cm, in addition to VS and including tumours
removed previously. Individuals who were diagnosed with
a central nervous system tumour before the age of 12 years
and had at least one other symptomatic tumour were also
rated as severe. Patients older than 30 years at presentation
with no more than two symptomatic or large tumours
[1.5 cm including VS and tumours excised previously
were assessed as mild. Moderate disease was classified as
not meeting mild or severe criteria [1, 3].
Genetic-rated severity
Genetic severity was rated as severe, moderate, or mild.
Truncating mutations in exons 1–13 in all cells were
rated as severe. Moderate disease included (1) deletion
not involving the promoter region or exon 1, (2) splice
site mutations in exons 1–8, and (3) mosaicism of
truncating mutations in exons 1–13 in blood. Mild dis-
ease was classified as (1) a missense mutation or an in-
frame deletion, (2) a large deletion involving the pro-
moter region or exon 1, (3) a splice-site mutation in
exons 9–15, (4) mosaicism (excluding moderate criteria),
and (5) no mutation identified on blood analysis [1, 6, 7,
15, 17–19].
Clinical assessment and NFTI-QOL
At each clinic visit, patients underwent clinical assessment
and completed the NFTI-QOL, an eight-item questionnaire
(and a free-response section) with a maximum score of 3
per item (four-point scale, range 0–3, with three as the most
impaired) and total score of 24 [14]. Patients who were
unable to complete the questionnaire due to visual or motor
difficulties were assisted by a specialist nurse.
Statistics
The NFTI-QOL, clinical, and genetic data were analysed
with SPSS using correlation, linear regression, and analysis
of variance (ANOVA) tools as required.
Results
Patient and visit numbers
Data were evaluated for 288 NF2 patients attending the
national NF2 clinics and satellite centres in England
(London, Oxford, Cambridge, Manchester) from 2010 to
2012. In total, there were 464 patient visits, including 288
(62.1 %) attending one visit, 117 (25 %) attending two
visits, 41 (8.9 %) with three visits, 14 (3 %) with four
visits, two patients (0.4 %) having five visits, and two
(0.4 %) attending six visits.
Gender, age, clinical- and genetic-rated severity
The studied group was comprised of 143 males and 145
females; the mean age was 42.2 years (SD 17.8) and the
age range was 16–87 years. There were no significant
differences in age or gender of the patients attending the
four different NF2 centres. Clinical- and genetic-rated
severity for 288 individuals with NF2 is shown in Table 2.
Thirty patients elected not to have genetic testing. There
were no significant differences in genetic-rated severity
between the four centres, but mean clinical severity
(ClinSev) was milder in the Manchester centre (1.5) than in
London (2.0), Cambridge (2.0), or Oxford (1.9) (Kruskal
Wallace test, df 3, v2 24.8, p \ 0.01).
NFTI-QOL
The mean NFTI-QOL score for 288 patients for the first
clinic visit was 8.7 (SD 5.4), for the 117 patients who
attended on a second visit it was 9.3 (SD 5.2), and for
all visits the mean NFTI-QOL was 9.2 (SD 5.4). This
was similar to the published norm of 9.4 (5.5), with no
significant relationships with age or gender. Analysis of
variance (ANOVA) revealed no differences in NFTI-
QOL scores for the four NF2 sites. Hearing loss, dizzi-
ness and balance, and impact of NF2 on role and outlook
on life were the items that showed the highest severity
ratings for all centres (Fig. 1). The evaluation of patient-
rated QOL (London) from visit 1 to visit 2 showed that
the majority of patients had stable disease. However,
three patients were significantly worse and three showed
significant improvement, as demonstrated by the 95 %
confidence intervals (CIs) for individuals with NF2
(Fig. 2). Examination of longitudinal changes indicated
that any NFTI-QOL score change up or down of greater
than five points would be statistically significant for an
individual (Fig. 2). The internal reliability of NFTI-QOL
was found to be very good, with a Cronbach’s alpha
score of 0.85 and re-test reliability r = 0.84. The NFTI-
QOL was related to ClinSev (r = 0.41, p \ 0.001;
Table 2 Clinical- and genetic-rated severity in 288 NF2 patients
Severity Clinical severity, n (%) Genetic severity, n (%)
Mild 124 (43.1) 168 (58.4)
Moderate 93 (32.3) 49 (17)
Severe 70 (24.3) 41 (14.2)
Not tested 0 30 (10.4)
Not classified 1 (0.3) 0 (0)
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r = 0.46 for all visits), but was only related weakly to
GenSev (r = 0.16, p \ 0.05; r = 0.15 for all visits).
Clinical severity in turn related to GenSev (r = 0.41,
p \ 0.001; r = 0.42 for all visits).
NFTI-QOL free responses
There were infrequent free responses, and where present,
they tended to amplify one of the eight NFTI-QOL
domains, rather than report new symptoms or problems.
One individual rated all domains as 0 on the first clinic
visit, despite complaining of worsening hearing, balance,
and role and outlook on life in the clinic. On the second
visit, staff found that the patient had not learnt to read at
school and that the total NFTI-QOL score was actually 6
when appropriate assistance was given for completion of
the questionnaire.
Discussion
In this 2-year longitudinal study, we assessed clinical-,
genetic-, and patient-rated disease severity in 288 patients
in four NF2 centres in England. We evaluated the mean
total and individual item NFTI-QOL scores for the four NF2
centres. This study did not reveal any significant difference
in the mean NFTI-QOL or individual item scores. NFTI-
QOL showed good internal reliability, good test–retest
reliability and demonstrated stability over time. Moreover,
the mean NFTI-QOL and individual item scores remained
stable for multiple visits, with no particular trend for
increase or decrease in items over time. Obviously, there
were wide variations in NFTI-QOL scores between indi-
viduals, reflecting different perceptions and coping mech-
anisms in response to chronic disease. Within the context of
the overall high reliability and stability of the NFTI-QOL,
an increase or reduction in scores was evident in some
individuals over time. The total NFTI-QOL score is the
optimum measure for estimating an individual’s overall
QOL and changes that occur over time. The clinician may
find it useful to evaluate the individual item scores to look
for changes in a particular domain, as this reflects the rel-
ative importance of that domain to the individual. Scores
vary with individual circumstances and ability of that
individual to cope with the impact of the disease on that
particular domain. For example, a 32-year-old male had
deteriorating total NFTI-QOL scores (from 13 to 16) until a
cochlear implant was inserted and specialist neuro-reha-
bilitation was undertaken for impaired mobility. The total
NFTI-QOL score reduced to 9 and individual item scores
improved for hearing, balance, mobility, and role and out-
look on life. This indicates the potential for NFTI-QOL to
detect changes in disease symptoms or response to treat-
ment. It also underlines the observation that improvement in
one domain, for instance hearing, may generalise to
improvements in other domains. There was a change of
more than five points in the total NFTI-QOL score in five
other patients, including four males and one female, aged
19–62 years (median age 38 years). The total NFTI-QOL
scores decreased in three individuals due to improved
hearing and balance and neurological symptoms. The total
NFTI-QOL scores increased in two patients with worsening
hearing, balance, and psychological issues that had a
Fig. 1 Mean item scores for NFTI-QOL in 288 patients on first visit
to London, Oxford, Cambridge, or Manchester NF2 centre
Fig. 2 NFTI-QOL scores are shown for NF2 individuals who
attended both visit 1 and visit 2 (n = 117). The thick line is the
fitted regression line and the thin lines on either side denote a 95 % CI
for individuals. The darker circles indicate superimposed observa-
tions for multiple NF2 individuals
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deleterious impact on their role and outlook in life. A five-
point change or greater was statistically significant for an
individual (95 % CI for individuals). However, this is a
statistical cutoff and smaller changes in scores could well
have clinical significance for an individual (Fig. 2).
Although NFTI-QOL correlates with ClinSev, it appears to
tap into more about the impact of NF2 on the individual,
rather than simply being a reflection of clinical and GenSev.
Overall, ClinSev was rated as milder for patients attending
the Manchester centre compared with London, Cambridge,
and Oxford, and this might simply reflect the disease het-
erogeneity. There was a weak correlation between NFTI-
QOL and GenSev. This could have arisen because GenSev
looks at the disease from a long-term perspective, whereas
the patient-rated NFTI-QOL mirrors current disease status.
The weaker correlation between NFTI-QOL and GenSev
might have arisen because some individuals with a mutation
predicting severe NF2 were assessed early in the course of
their disease and had not yet developed many symptoms or
deficits. Furthermore, individuals with genetic mutations
associated with mild disease, may still have significant
clinical symptoms and neurological deficit, albeit with a
lower tumour burden and older age at presentation. One
might expect that anxiety and depression would be a major
feature of NF2, and this is the case for some. However, the
mean item score for anxiety and depression for all visits was
low, and this likely reflects the high levels of psychological,
psychiatric, and educational support available to people
attending the national NF2 centres. Most patients did not
have visual problems and the mean NFTI-QOL score for
sight was low, but it was reported as a major problem for a
minority of individuals particularly when it compounded
hearing loss. Disease specific QOL questionnaires are an
important tool for evaluating patient focused outcomes of
intervention. If a new agent is capable of shrinking a tumour
but the patient does not experience an improvement in
symptoms or QOL, careful thought should be put into
continuing administration of the drug, unless it reduces
mortality rates. One of our patients had a significant
reduction in size of a VS following 3 months of treatment
with bevacizumab; nonetheless, the total NFTI-QOL score
remained 22, as the patient had not noted improvement in
any of the NFTI-QOL domains. NFTI-QOL is validated for
people with NF2 16 years and older, but potentially could
be extended for use in 12-year-olds. The cohort of younger
children with NF2 is small, and current clinical trials are
focused on teenagers and adults. Further work would be
required to develop a disease-specific NF2 QOL question-
naire in this younger age group. This is because visual
impairment, neurological deficit from amyotrophy, central
nervous system ependymomas, and meningiomas may be
more prominent findings than hearing, loss of balance, and
dizziness from VS [1, 3].
Conclusions
NFTI-QOL is a disease-specific questionnaire that is quick
and easy to administer. It shows good reliability and has
the ability to detect significant changes over time in QOL
of individual patients. We have demonstrated previously
that NFTI-QOL correlates strongly and significantly with
all domains of the SF-36 and with the EuroQOL, generic
questionnaires that do not focus on NF2-specific problems
[13, 16]. The moderate relationship between NFTI-QOL
and ClinSev and genetic-rated severity was consistent with
the notion that NFTI-QOL draws on other dimensions of
NF2 patient experiences that are not covered by either of
these latter measures.
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